Keyword: Visterra

Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.

Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.

The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.

Visterra has begun efforts to bounce back from its failed IPO attempt by securing a contract from CARB-X.

Tocagen has filed to raise up to $86 million in an IPO to take its brain cancer gene therapy combination through the first part of a phase 2/3 trial.